TC314 Evaluation of P450 Humanized Immune Deprived Mouse Model (8HUM/Rag2-/-) in Efficacy Screening of Anti-malarials
TC309 In Vitro Screening-based Selection and In Vivo Efficacy Evaluation of Bacteriophages as Potential New Assets in the Topical Treatment of Buruli Ulcer Disease.
TC310 Enabling Cryptococcal Meningitis Drug Discovery: Development of Cryptococcus Screening Cascade and Identification of High-quality Starting Points for Drug Discovery
TC305 Investigating combination antimicrobial therapy for treating infection caused by invasive non-typhoidal Salmonella disease in sub-Saharan Africa
TC302 Therapeutic exploitation of autophagy modulators
TC288 Designing optimal regimes for tuberculosis therapy using one-step high content dynamic in vitro kill kinetic assay linked to hollow fiber studies
TC279 Deconvoluting the Mode-of-action of Novel Anti-Chagas and Anti-leishmanial Compounds
TC298 Development of a Drug Discovery Platform Targeting Salmonella Typhimurium Persister Cells
TC295 Harvard T.H. Chan School of Public - Understanding the development of drug resistance in liver stages of Plasmodium falciparum
TC292 Malaria Lead Discovery Engine : A Fast track approach to identify novel antimalarial chemical classes with multi-stage activity
TC283 Tebipenem-pivoxil as an alternative to ceftriaxone for clinically non-responding children with shigellosis
TC290 DnaJ-DnaK-GrpE complex as a selective drug target in Mycobacterium tuberculosis
TC281 Shortening and improving compliance to Buruli Ulcer therapy- Four weeks daily triple betalactam
TC277 Recapitulation of ATQ infection results using TCOL mosquitoes/parasites/facilities
TC287 Evaluation of P450 humanized mouse model (8HUM) as a tool to assess the impac
TC257 High-throughput screen for small molecules that alter the shape of enteric bacterial pathogens
TC269 Generation, characterization and in vivo evaluation of a novel live malaria vaccine
TC275 Microbiome restoration therapeutics for environmental enteric dysfunction (EED) and associated stunted childhood growth
TC273 Design of novel inhibitors of Shigella LpxC
TC267 Antimalarial drug discovery targeting pre-erythrocytic stages of Plasmodium falciparum
TC264 University of Washington - High Throughput Screening for Inhibitors of Shigella Virulence Determinants
TC263 Hit-to-Lead Development of the Kalihinol Scaffold for Malaria Treatment
TC266 A chemogenomic overexpression screen to identify malaria liver stage targets
TC261 IBR-CONICET_UNR Instituto de Biología Molecular y Celular de Rosario - Trypanosoma cruzi bromodomains: druggable readers to look out!
TC262 TB antivirulence therapeutics: small molecule inhibitors against M. tuberculosis replication and persistence pathways as novel alternatives to classic antibiotics.
TC249 Targeting Virulence Regulators as a Novel Approach to Antibiotics for Shigellosis
TC255 Unravelling new combinatorial therapies against Shigellosis
TC247 University of Georgia + Bioaster- Chagas AABLO (Chagas AcylAminoBenzothiazol Lead Optimization)
TC256 Predicting optimal dosing schedules and clinical outcomes of beta‐lactams for TB therapy using PKPD and mechanistic models Carbapenem vs. cephem: the beta‐lactam paradigm
TC232 Utrecht University - Attacking Shigella by blocking its disease causing Toxin
TC246 PK/PD modeling for anti-Shigella drug candidates
TC241 Structural biology and assays enabling β-lactams that target Mycobacteria tuberculosis
TC237 Biomedical Primate Research Centre- Optimization of hepatocyte culture to support drug screening for malaria hypnozoites
TC236 University of Melbourne - High throughput screening to identify selective proteasome inhibitors as new antimalarials with a novel mode of action
TC239 Hit discovery for new antimicrobials against Shigella spp
TC217 London School of Hygiene and Tropical Medicine - Optimization of imidazopyridine and thiazole scaffolds targeting plasmodial kinases to generate a fast killing compound to treat malaria infection and block transmission
TC189 CNRS / Institut de Biologie Structurale and Harvard Medical School - Biochemical and Structural Characterization of Mtb ClpC1P1P2 and ClpXP1P2 inhibitors - first step towards new TB therapeutics
TC214 University of Birmingham - Exploring TB Space: Optimization of novel, high quality phenotypic hits (EXPTBS)
TC216 University of Birmingham - Whole cell protein synthesis inhibition assay for high-throughput drug discovery
TC193 University of Alabama at Birmingham - Self-poisoning of Mycobacterium tuberculosis by inhibiting siderophore secretion
TC215 University of Georgia - Rapid selection of in vivo active anti-Trypanosoma cruzi compounds
TC192 Birmingham University (initially Swiss Federal Institute of Technology in Zürich - ETHZ) - Optimisation of Fidaxomicin analogs
TC188 University of British Columbia - Intra-macrophage driven optimization of confirmed hit GSK421197A
TC206 University of Birmingham - ChemPro_Target_ID - A Chemical Proteomics Approach to Confirm – or Otherwise – the Results of Whole-Genome Sequencing of Spontaneous Resistant Mutants Generated Against Hits from a Phenotypic Screening Campaign: Is MmpL3 Really the Target for Such a Diverse Ran
TC194 IQUIBICEN-CONICET, Dept of Biological Chemistry, School of Exact and Natural Science, University of Buenos Aires.
TC197 London School of Hygiene and Tropical Medicine (LSHTM) - Mode of action and target identification of anti-Chagasic compounds
TC164 T. brucei drug discovery: ADMET and PK support for hit-to-lead optimization
TC185 Structural Genomics Consortium - Identification of small molecule inhibitors targeting plasmodium methyltransferase SET1 and elongation factor 2
TC178 “Severo Ochoa” Molecular Biology Center and University of León - Small-molecule screening against Visceral Leishmaniasis using ex-vivo splenic explant cultures
TC181 Phenotypic screening to identify small molecule inhibitors of Visceral Leishmaniasis and Chagas disease
TC167 Screening and identification of inhibitors of the Plasmodium falciparum cGMP-dependent protein kinase (PfPKG) as novel antimalarial drugs
TC162 University of Dundee
TC135 Development of a platform dedicated to translate the transmission blocking (TB) efficacy of anti‐P. falciparum drugs to P. vivax
TC152 Turning small potent antimycobacterial cyclo(depsi)peptides into drug-like scaffolds
TC180 National Institute of Blood Transfusion & INSERM - BlockBackMalaria” - Block rings and gametocytes in the spleen to block Malaria
TC134 Reversal of Artemisinin Resistance by means of Chemical Genetics
TC156 Studies towards the identification of orally available I-lactams with efficacy against Mycobacterium tuberculosis
TC150 Hit to Lead Optimization for kinetoplastid diseases: single agents for Chagas and HAT
TC189 Harvard Medical School
TC149 Identification of small-molecule inhibitors of Plasmodium N-myristoyltransferase
TC144 The development of synergistic combinations of rifampicin and cephalosporins against Mycobacterium tuberculosis
TC130 Hit-to-lead optimisation of a small-molecule inhibitor targeting the M. tuberculosis aspartyl-tRNAAsp synthetases
TC113 An Open Source Hit-to-Lead campaign in Tuberculosis drug discovery
TC132 Use of metabolomics to determine modes of action of novel anti?leishmanial compounds
TC125 Screening of PfCLK
TC112 Whole-cell assays for the identification and classification of Mtb growth inhibitors
TC109 Identifying and developing partner drugs for pyrimidine biosynthesis inhibitors that supress the development of resistance in Pf
TC050 Modulation of trypanosomal cAMP signalling for sleeping sickness therapeutic discovery
TC096 New Medicines for TB through Rifamycin semisynthesis
TC111 Development of a liver stage mouse model for Plasmodium falciparum
TC048 Florida International Univ - Identification of inhibitors of M tuberculosis topoisomerase I for novel anti-TB therapy
TC054 Targeting the trypanosome editosome for drug discovery
TC055 HTS for new small molecules enabling eradication of M tuberculosis inside infected macrophages
TC053 Development of anti-T cruzi drugs targeting fatty acid utilization
TC029 A metabolomic approach to decipher Mtb permeability
TC045 Identifying benzimidazole-derived leads against P falciparum
TC049 Optimization of a class of oxadiazole compounds target
TC046 Assay development of in vivo rate of killing of intracellular Leish and T cruzi spp by standard and novel chemical entities
TC044 Antitubercular BirA inhibitors
TC027 Identification of potent and specific inhibitors of Mtb DHFR
TC042 TCAMS triazole series as potential serine protease inhibitors
TC028 Hit to Lead development for a new class of antimycobacterial agents
TC030 Identification of Mtb Leucyl-tRNA synthetase inhibitors
TC008 Identification of hits for T cruzi
TC002 IPCS-kinetoplastid target
TC007 mTOR/PI3K inhibitors for kinetoplastids
TC003 In vitro culture for P vivax
TC001 Ubiquitylation profile of Pf and Mtb infected cells
TC297 University of Oxford - Studies on Nucleophilic Cysteine Enzymes Involved in Bacterial Cell Wall Biosynthesis- iCASE
TC285 Optimisation of a screen for antimicrobials that enhance pyrazinamide activity against Mycobacterium tuberculosis